RecruitingRectal Cancer
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
Eligible age
18–90 yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This trial (molecular characterization trial) focuses on rectal cancer, a common cancer that is treated with radiotherapy (RT) as standard of care and represents a setting in which to study the effects of RT on the immune system.
Sponsor: Weill Medical College of Cornell University
You may qualify if…
- ✓ Histologically confirmed diagnosis of adenocarcinoma of the rectum
- ✓ Age ≥ 18 years
- ✓ ECOG performance status 0-1
- ✓ cT2-T3N0 or cT1-3N1 or cT4 or cN2
- ✓ Rectal cancer amenable to total mesorectal excision
- ✓ No evidence of distant metastases
- ✓ No prior pelvic radiation therapy
- ✓ No prior chemotherapy or surgery for rectal cancer
You may not qualify if…
- ✕ Recurrent rectal cancer
- ✕ Primary unresectable rectal cancer is defined as a primary rectal tumor which, on the basis of either physical exam or pelvic MRI, is deemed to be adherent or fixed to adjacent pelvic structures (en bloc resection will not be achieved with negative margins).
- ✕ Patients who have received prior pelvic radiotherapy
- ✕ Patients with prior allogenic stem cell or solid organ transplantation.
- ✕ Patients receiving treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor-α agents) administered at \>10 mg/day prednisone or equivalent within 2 weeks prior to initiation of study treatment.
- ✕ Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment would make them inappropriate candidates for entry into this study
- ✕ Patients receiving other anticancer or experimental therapy. No other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-VEGF/Flk-1 monoclonal antibody, or other experimental drugs) of any kind are permitted while the patient is receiving study treatment.
- ✕ Women who are pregnant or breastfeeding. Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and for up to four weeks after the study.
Where it's recruiting
Source: ClinicalTrials.gov · NCT05943210 · last updated 2026-06-15